BACK
Project/Company Name
Restore Biotechnology Limited 復元生物技術有限公司
Project Leader
Source of Funding/Programme
TSSSU
Description
translating newly discovered molecular insights into innovative drug development for fibrotic diseases. Fibrosis can cause dysfunction in multiple organs, leading to significant morbidity and mortality. The disease burden associated with fibrosis is substantial, and existing treatments are often inadequate. One of the key regulators of fibrosis is CTGF (Connective Tissue Growth Factor). The project team has developed a next-generation CTGF inhibitor, RES001, which has demonstrated efficacy in a muscle fibrosis model, and received Orphan Drug and Rare Pediatric Disease Designation from FDA.
Project/Company Name
Restore Biotechnology Limited 復元生物技術有限公司
Project Leader
Source of Funding/Programme
TSSSU
Description
translating newly discovered molecular insights into innovative drug development for fibrotic diseases. Fibrosis can cause dysfunction in multiple organs, leading to significant morbidity and mortality. The disease burden associated with fibrosis is substantial, and existing treatments are often inadequate. One of the key regulators of fibrosis is CTGF (Connective Tissue Growth Factor). The project team has developed a next-generation CTGF inhibitor, RES001, which has demonstrated efficacy in a muscle fibrosis model, and received Orphan Drug and Rare Pediatric Disease Designation from FDA.
Starting Year
2025
Business Area
Biotech
Nature
TSSSU Company